provider portal
Wesper Journal
Discover how Zepbound® (tirzepatide), the first FDA-approved medication for obstructive sleep apnea (OSA) in adults with obesity, is revolutionizing treatment. Combining effective weight management with symptom relief, Zepbound offers a groundbreaking solution that enhances sleep quality, simplifies care pathways, and improves overall health outcomes. Learn more about this transformative advancement in OSA therapy.
Continue reading
GLP-1 receptor agonists, such as Zepbound (tirzepatide), represent a groundbreaking advancement in managing Obstructive Sleep Apnea (OSA). These medications not only promote significant weight loss, which reduces airway obstruction but may also improve neuromuscular control of breathing. Traditionally treated with mechanical interventions like CPAP, OSA care now benefits from a more comprehensive approach.
The FDA-approved Zepbound has demonstrated substantial reductions in apnea events and weight-related contributors to OSA, offering an alternative for patients who struggle with CPAP therapy. Advanced tools like Wesper, a wearable sleep monitoring system, further enhance OSA management by providing real-time insights and personalized feedback.
This dual-action approach—combining pharmaceutical innovation with cutting-edge technology—signals a transformative shift in sleep medicine, offering hope for millions affected by OSA worldwide.
Continue reading
Periodic Limb Movement Disorder (PLMD) is a neurological condition characterized by involuntary leg movements during sleep, which disrupt sleep and lead to daytime fatigue. Often linked with other disorders like Restless Legs Syndrome (RLS) and Obstructive Sleep Apnea (OSA), PLMD can worsen overall sleep quality and cognitive function. Diagnosing PLMD typically involves a polysomnography (PSG) sleep study, but new innovations like Wesper Lab offer a convenient, at-home screening tool to detect potential PLMD. Wesper uses biosensor technology to monitor leg movements and provide valuable insights for early detection, making it an accessible option for healthcare providers to improve patient outcomes.
Continue reading
Discover how Zepbound® (tirzepatide), the first FDA-approved medication for obstructive sleep apnea (OSA) in adults with obesity, is revolutionizing treatment. Combining effective weight management with symptom relief, Zepbound offers a groundbreaking solution that enhances sleep quality, simplifies care pathways, and improves overall health outcomes. Learn more about this transformative advancement in OSA therapy.
Continue reading
Obstructive sleep apnea (OSA) has been linked to an increased risk of cancer, with individuals suffering from OSA being 1.53 times more likely to receive a cancer diagnosis. The mechanisms involve intermittent hypoxia and inflammation, which can foster an environment...
Continue reading
